Connection
Jennifer Laudadio to Antineoplastic Agents
This is a "connection" page, showing publications Jennifer Laudadio has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.041 |
|
|
|
-
Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Int J Oncol. 2013 Dec; 43(6):2057-63.
Score: 0.017
-
Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009 Sep 24; 114(13):2598-605.
Score: 0.013
-
Quigley NB, Henley DC, Hubbard RA, Laudadio J, Press RD. ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. J Mol Diagn. 2008 Sep; 10(5):475-6; author reply 476.
Score: 0.012